Development of Room Temperature Stable Formulation of Formoterol Fumarate/Beclomethasone HFA pMDI
نویسندگان
چکیده
Various solubilizers were tried during preformulation study. Propylene glycol and Transcutol were selected as solubilizers for further study. Poloxamer 407 gives gelation temperature in nasal temperature range 280 to 350 in 18% w/v concentration. Addition of bioadhesive polymer from 0.2% to 0.7% further lowered the gelation temperature from 340 to 290. Gelation temperatures obtained using two different methods (visual inspection and rheological method) did not vary more than ±10. The gelation temperature lowering effect of bioadhesive polymer might have caused in part by the increased viscosity after dissolution of mucosadhesive polymer. The pH values of all formulations were found in the range of 5.3 to 5.6. Formulation should posses’ mild acidic pH for activation of lysozyme (A natural antibacterial enzyme important for controlling nasal microbial count which becomes inactive at alkaline pH). The pKa of ondansetron hydrochloride is 7.4; so drug present in solubilised form in pH range 5 to 6.5 (ondansetron hydrochloride precipitate above 6.8). It was observed that the concentration of bioadhesive polymer increased from 0.2% to 0.7% showed retardation of ondansetron hydrochloride release, probable mechanism for such retardation of release may be reduction in number and dimensions of the channels in gel structure by increased viscosity of the formulation. From the study it can be concluded that the nasal in situ gels can be formulated of ondansetron hydrochloride using PF127 and bioadhesive polymer.
منابع مشابه
Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma
BACKGROUND Budesonide/formoterol is an effective treatment for both asthma and chronic obstructive pulmonary disease. This study compared the efficacy and safety of a novel hydrofluoroalkane (HFA) pressurised metered-dose inhaler (pMDI) formulation of budesonide/formoterol with that of budesonide pMDI and budesonide/formoterol dry-powder inhaler (DPI; Turbuhaler). METHODS This was a 12-week, ...
متن کاملHigh strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids
BACKGROUND A high strength of beclomethasone/formoterol fumarate (BDP/FF) in a pressurised metered dose inhaler (pMDI), which contains extrafine BDP (200 μg/actuation) and FF (6 μg/actuation) has been developed to treat those asthmatics who are not adequately controlled on previous treatments. METHODS A 12-week, randomized, double-blind, parallel group study was performed to compare the effic...
متن کاملMAXIFLO Inhaler
MAXIFLO-125 Inhaler Each actuation delivers: Formoterol Fumarate Dihydrate IP..................6 mcg Fluticasone Propionate IP............................125 mcg Suspended in propellant HFA 134a ...............q.s. MAXIFLO-250 Inhaler Each actuation delivers: Formoterol Fumarate Dihydrate IP .................6 mcg Fluticasone Propionate IP...........................250 mcg Suspended in propella...
متن کاملAsthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation
BACKGROUND Although patients have more problems using metered dose inhalers, clinical comparisons suggest they provide similar control to dry powder inhalers. Using real-life situations this study was designed to evaluate asthma control in outpatients with moderate to severe persistent asthma and to compare efficacy of fixed combinations of inhaled corticosteroids (ICS) and long acting beta-ago...
متن کاملBeclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma.
The present study was designed to compare the fixed combination of beclomethasone and formoterol in a hydrofluoroalkane Modulite (Chiesi Farmaceutici, Parma, Italy) pressurised metered-dose inhaler (pMDI), with a combination of budesonide and formoterol administered via a Turbuhaler (AstraZeneca, Lund, Sweden) dry powder inhaler (DPI). This was a phase III, multinational, multicentre, double-bl...
متن کامل